Literature DB >> 10882024

(Partial) agonist/antagonist properties of novel diarylalkyl carbamates on histamine H3 receptors.

A Sasse1, H Stark, X Ligneau, S Elz, S Reidemeister, C R Ganellin, J C Schwartz, W Schunack.   

Abstract

In the search for new ligands of the histamine H3 receptor, novel diarylalkyl carbamates (1-19) were synthesized as derivatives of 3-(1H-imidazol-4-yl)propanol and -ethanol. Carbamates were built up via isocyanates either from corresponding amines by reaction with diphosgene or from related carboxylic acid/diphenylphosphoryl azide and the alcoholic component. Sterically hindered amines were prepared in a two-step reaction sequence from corresponding ketones. Some of the title compounds showed (partial) agonist activity at the histamine H3 receptor in vitro and in vivo. Diphenylmethyl carbamate 2 was identified as a new lead structure (ED50 = 5.3 +/- 2.6 mg/kg po, alpha = 1.0). Aromatic substitution in ortho- or para-positions of 2 led to a loss of agonist activity. meta-Substitution was tolerated to some extent. These effects seemed to be caused by steric rather than electronic properties of the substituents. An investigation of exchange of one or both phenyl rings of 2 by heterocyclic rings led to the highly active and selective thienyl derivative 18 (ED50 3.4 +/- 1.4 mg/kg p.o., alpha = 1.0). These new (partial) agonists of the histamine H3 receptor might serve as pharmacological tools for investigating molecular aspects of the H3 receptor or as possible centrally acting therapeutic agents with oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882024     DOI: 10.1016/s0968-0896(00)00050-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  High-affinity carbamate analogues of morphinan at opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

2.  Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.

Authors:  T Nickel; U Bauer; E Schlicker; M Kathmann; M Göthert; A Sasse; H Stark; W Schunack
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Identification and characterization of ZEL-H16 as a novel agonist of the histamine H3 receptor.

Authors:  Ying Shi; Rong Sheng; Tingting Zhong; Yu Xu; Xiaopan Chen; Dong Yang; Yi Sun; Fenyan Yang; Yongzhou Hu; Naiming Zhou
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.